SecurityCYTX / Cytori Therapeutics, Inc. (23283K105)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding61,622,799 shares (as of 2018-03-31)
Total Insiders17
Total Directors9
Total Officers6

Stock Insider Trading (from SEC Form 4)

Cytori Therapeutics, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CYTX / Cytori Therapeutics, Inc. insiders include MARTELL RON, PostFinance AG Lim Kian Thiam, LYONS GARY A, Marino Mark, HAYDEN JEREMY B., HARRIS JOHN DAVID, Swissquote Bank SA, Girao Tiago, Thompson Tommy G, LAPOINTE ANTHONY GREGG, and KESTEN STEVEN, HAWRAN PAUL W, Naughton Gail K, Hawkins Richard J, HEDRICK MARC H, RICKEY DAVID, .

Insider Roster

Insider Dir Off 10% Shares Owned
PostFinance AG 10% Owner
X 4,543,086
LYONS GARY A Director
X
Swissquote Bank SA 10% Owner
X 5,328,229
RICKEY DAVID Director
X
Naughton Gail K Director
X
HEDRICK MARC H President and CEO, Director
X X
Hawkins Richard J Director
X
HARRIS JOHN DAVID VP and GM Cell Therapy
X
Girao Tiago VP & Chief Financial Officer
X
LAPOINTE ANTHONY GREGG Director
X
Marino Mark Chief Medical Officer
X
HAYDEN JEREMY B. General Counsel & VP of BD
X
MARTELL RON Director
X
HAWRAN PAUL W Director
X
KESTEN STEVEN Exec VP and Chief MO
X
Thompson Tommy G Director
X
Lim Kian Thiam 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-02-14 4 PostFinance AG S D 0.3398 -473,831 4,543,086 1,543,741
2018-02-13 4 PostFinance AG S D 0.3112 -101,710 5,016,917 1,561,265
2018-02-12 4 PostFinance AG S D 0.3148 -185,272 5,118,627 1,611,344
2018-02-09 4 PostFinance AG S D 0.34 -7,552 5,303,899 1,803,326
2018-02-08 4 PostFinance AG S D 0.3431 -228,603 5,311,451 1,822,359
2018-01-11 4 Swissquote Bank SA S D 0.34 -20,000 5,328,229 1,811,598
2018-01-11 4 Swissquote Bank SA S D 0.34 -12,630 5,348,229 1,818,398
2018-01-11 4 Swissquote Bank SA S D 0.3406 -20,000 5,360,859 1,825,909
2018-01-11 4 Swissquote Bank SA S D 0.3405 -20,000 5,380,859 1,832,182
2018-01-10 4 Swissquote Bank SA S D 0.3803 -15,796 5,400,859 2,053,947
2018-01-09 4 Swissquote Bank SA S D 0.3902 -20,000 5,416,655 2,113,579
2018-01-09 4 Swissquote Bank SA S D 0.3964 -20,000 5,436,655 2,155,090
2018-01-09 4 Swissquote Bank SA S D 0.38 -20,000 5,456,655 2,073,529
2018-01-09 4 Swissquote Bank SA S D 0.38 -20,000 5,456,655 2,073,529
2018-01-09 4 Swissquote Bank SA S D 0.37 -20,000 5,496,655 2,033,762
2016-08-10 4 HARRIS JOHN DAVID P D 2.03 2,500 7,000 14,210
2016-06-15 4 LYONS GARY A By Trust X I 1,900 4,358
2016-06-14 4 RICKEY DAVID By Trust P I 2.10 5,000 73,230 153,783
2016-06-15 4 RICKEY DAVID By Trust X I 16,000 71,226
2016-06-15 4 RICKEY DAVID By Charitable Trust X I 6,000 24,004
2016-06-15 4 HEDRICK MARC H By Family Trust X I 41,305 83,133
2016-06-14 4 Naughton Gail K P D 2.10 1,000 2,400 5,040
2016-06-15 4 Hawkins Richard J X D 3,356 8,435
2016-06-15 4 Girao Tiago X D 5,667 14,084
2016-06-15 4 HAYDEN JEREMY B. X D 1,896 3,643
2016-06-15 4 KESTEN STEVEN X D 200 3,881
2016-06-15 4 HARRIS JOHN DAVID X D 2,500 4,500
2016-05-13 4 HARRIS JOHN DAVID P D 2.71 2,000 2,000 5,420
2016-03-09 4 RICKEY DAVID By Charitable Trust P I 0.1886 50,000 1,023,444 193,022
2016-03-09 4 RICKEY DAVID By Trust P I 0.1886 100,000 1,023,444 193,022
2016-01-28 4 KESTEN STEVEN A D 47,000 55,201
2016-01-28 4 Girao Tiago A D 35,250 123,250
2016-01-28 4 HEDRICK MARC H A D 70,500 627,411
2015-09-03 4 Thompson Tommy G By LLC P I 0.3745 25,449 83,600 31,308
2015-09-02 4 HAYDEN JEREMY B. P D 0.355 8,200 26,200 9,301
2015-08-28 4 RICKEY DAVID By Trust P I 0.3148 21,000 653,385 205,686
2015-08-28 4 RICKEY DAVID By Charitable Foundation P I 0.3148 35,000 220,059 69,275
2015-08-28 4 HEDRICK MARC H By Family Trust P I 0.31 1,200 556,911 172,642
2015-08-27 4 HEDRICK MARC H By Family Trust P I 0.3052 10,000 555,711 169,603
2015-08-27 4 RICKEY DAVID By Trust P I 0.2992 50,000 632,385 189,210
2015-08-26 4 RICKEY DAVID By Trust P I 0.327 25,000 582,385 190,440
2015-08-21 4 HEDRICK MARC H By Family Trust P I 0.35 5,000 545,711 190,999
2015-08-21 4 RICKEY DAVID By Trust P I 0.375 50,000 557,385 209,019
2015-08-21 4 HEDRICK MARC H By Family Trust P I 0.38 5,000 540,711 205,470
2015-08-19 4 HAYDEN JEREMY B. P D 0.392 18,000 18,000 7,056
2015-08-20 4 HEDRICK MARC H By Family Trust P I 0.40 9,700 535,711 214,284
2015-08-20 4 HEDRICK MARC H By Family Trust P I 0.399 300 526,011 209,878
2015-08-19 4 RICKEY DAVID By Trust P I 0.3934 48,600 507,385 199,605
2015-08-19 4 KESTEN STEVEN By Family Trust P I 0.3871 6,000 8,201 3,175
2015-08-18 4 HEDRICK MARC H By Family Trust P I 0.395 9,900 525,711 207,656
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] (25-1)

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

2018-03-16 reuters
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO’S PLANS FOR HABEO CELL THERAPY - SEC FILING (25-0)

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Fourth Quarter and Full-Year 2017 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions]. (25-0)

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board

2018-01-29 reuters
* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD (25-2)